Promising clinical trials are currently in progress for FTD targeting TDP-43 and tau, investigating treatment approaches including tau vaccines, inhibitors of tau phosphorylation and acetylation, tau-antibodies, and agents that stabilize microtubules. Here, MAPT is linked to frontotemporal dementia.